Madison Avenue Partners
Latest statistics and disclosures from Madison Avenue Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are GHC, SN, TBPH, WLY, HES, and represent 70.21% of Madison Avenue Partners's stock portfolio.
- Added to shares of these 9 stocks: WLY (+$52M), GMED (+$38M), NNI (+$28M), HMST (+$14M), TSVT, ATMU, INDV, CEE, GHC.
- Started 5 new stock positions in GMED, HMST, NNI, ATMU, WLY.
- Reduced shares in these 10 stocks: SN (-$117M), IART (-$45M), , VSTS (-$29M), Mirati Therapeutics (-$25M), Merrimack Pharma, ONL, GOSS, Selecta Biosciences, Safeguard Scientifics.
- Sold out of its positions in VSTS, GIII, IART, Mirati Therapeutics, Safeguard Scientifics, Selecta Biosciences.
- Madison Avenue Partners was a net seller of stock by $-124M.
- Madison Avenue Partners has $620M in assets under management (AUM), dropping by -12.48%.
- Central Index Key (CIK): 0001801265
Tip: Access up to 7 years of quarterly data
Positions held by Madison Avenue Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Madison Avenue Partners
Madison Avenue Partners holds 18 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Graham Hldgs Com Cl B (GHC) | 26.1 | $162M | 211k | 767.68 |
|
|
| Sharkninja Com Shs (SN) | 18.2 | $113M | -50% | 1.8M | 62.29 |
|
| Theravance Biopharma (TBPH) | 10.1 | $63M | 7.0M | 8.97 |
|
|
| Wiley John & Sons Cl A (WLY) | 8.4 | $52M | NEW | 1.4M | 38.13 |
|
| Hess (HES) | 7.4 | $46M | 300k | 152.64 |
|
|
| Stagwell Com Cl A (STGW) | 7.2 | $45M | 7.1M | 6.22 |
|
|
| Globus Med Cl A (GMED) | 6.1 | $38M | NEW | 703k | 53.64 |
|
| Nelnet Cl A (NNI) | 4.4 | $28M | NEW | 290k | 94.65 |
|
| Homestreet (HMST) | 2.2 | $14M | NEW | 905k | 15.05 |
|
| 2seventy Bio Common Stock (TSVT) | 2.1 | $13M | +38% | 2.4M | 5.35 |
|
| Ovid Therapeutics (OVID) | 1.8 | $11M | 3.6M | 3.05 |
|
|
| Orion Office Reit Inc-w/i (ONL) | 1.5 | $9.2M | -12% | 2.6M | 3.51 |
|
| Franklin Street Properties (FSP) | 1.2 | $7.5M | 3.3M | 2.27 |
|
|
| Merrimack Pharmaceuticals Com New | 0.9 | $5.7M | -29% | 387k | 14.77 |
|
| Gossamer Bio (GOSS) | 0.8 | $4.9M | -18% | 4.1M | 1.18 |
|
| Central Europe and Russia Fund (CEE) | 0.6 | $4.0M | +54% | 423k | 9.52 |
|
| Indivior Ord (INDV) | 0.6 | $3.5M | +125% | 163k | 21.42 |
|
| Atmus Filtration Technologies Ord (ATMU) | 0.4 | $2.5M | NEW | 77k | 32.25 |
|
Past Filings by Madison Avenue Partners
SEC 13F filings are viewable for Madison Avenue Partners going back to 2019
- Madison Avenue Partners 2024 Q1 filed May 15, 2024
- Madison Avenue Partners 2023 Q4 filed Feb. 16, 2024
- Madison Avenue Partners 2023 Q3 filed Nov. 14, 2023
- Madison Avenue Partners 2023 Q2 filed Aug. 14, 2023
- Madison Avenue Partners 2023 Q1 filed May 15, 2023
- Madison Avenue Partners 2022 Q4 filed Feb. 14, 2023
- Madison Avenue Partners 2022 Q3 filed Nov. 14, 2022
- Madison Avenue Partners 2022 Q2 filed Aug. 15, 2022
- Madison Avenue Partners 2022 Q1 filed May 16, 2022
- Madison Avenue Partners 2021 Q4 filed Feb. 14, 2022
- Madison Avenue Partners 2021 Q3 filed Nov. 15, 2021
- Madison Avenue Partners 2021 Q2 filed Aug. 16, 2021
- Madison Avenue Partners 2021 Q1 filed May 17, 2021
- Madison Avenue Partners 2020 Q4 filed Feb. 12, 2021
- Madison Avenue Partners 2020 Q3 filed Nov. 16, 2020
- Madison Avenue Partners 2020 Q2 filed Aug. 14, 2020